Phospholipase A2 pathway association with macrophage-mediated polycarbonate-urethane biodegradation
Source abstract
Abstract
Activation of the phospholipase A2 (PLA2) pathway is a key cell signaling event in the inflammatory response. The PLA2 family consists of a group of enzymes that hydrolyze membrane phospholipids, resulting in the liberation of arachidonic acid (AA), a precursor to pro-inflammatory molecules. Given the well-documented activating role of biomaterials in the inflammatory response to medical implants, the present study investigated the link between PLA2 and polycarbonate-based polyurethane (PCNU) biodegradation, and the effect that material surface had on PLA2 activation in the U937 cell line. PCNUs were synthesized with poly(1,6-hexyl 1,2-ethyl carbonate)diol, 1,4-butanediol and one of two diisocyanates (hexane 1,6-diisocyanate or 4,4'-methylene bisphenyl diisocyanate) in varying stoichiometries and incubated with adherent U937 cells. PLA2 inhibiting agents resulted in significantly decreased PCNU biodegradation (p < 0.05). Moreover, when activation of PLA2 was assessed (3H-AA release), significantly more 3H-AA was released from PCNU-adherent U937 cells than polystyrene-adherent U937 cells (p < 0.05) which was significantly decreased in the presence of PLA2 inhibitors. The pattern of inhibition of U937 cell-mediated biodegradation and 3H-AA release that was modulated by PCNU surface differences, suggests a role for secretory PLA2 along with cytosolic PLA2. Understanding PCNU activation of intracellular pathways, such as PLA2, will allow the design of materials optimized for their intended use.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Bone health and treatments · Inflammatory mediators and NSAID effects · Bone and Dental Protein Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (32)
Show source-provided references
1. Diversity of group types, regulation, and function of phospholipase A210.1016/S0021-9258(17)36794-7 ↗
2. Regulation and inhibition of phospholipase A210.1146/annurev.pharmtox.39.1.175 ↗
3. Phospholipase A2––a mediator between proximal and distal effectors of inflammation
4. Possible role of arachidonic acid and of phospholipase A2 in the control of lysosomal enzyme release from human polymorphonuclear leukocytes
5. Mechanisms of inflammation and infection with implanted devices10.1016/1054-8807(93)90045-4 ↗
6. Model systems to assess the destructive potential of human neutrophils and monocyte-derived macrophages during the acute and chronic phases of inflammation10.1002/1097-4636(200102)54:2<189::AID-JBM5>3.0.CO;2-8 ↗
7. A review of the biostability and carcinogenicity of polyurethanes in medicine and the new generation of ‘biostable’ polyurethanes10.1163/156856294X00347 ↗
8. Hydrolytic degradation of poly(carbonate)-urethanes by monocyte-derived macrophages10.1016/S0142-9612(01)00049-7 ↗
9. A new drug delivery system with controlled release of antibiotic only in the presence of infection10.1002/(SICI)1097-4636(199810)42:1<112::AID-JBM14>3.0.CO;2-N ↗
10. Human macrophage-mediated biodegradation of polyurethanes10.1016/S0142-9612(02)00137-0 ↗
11. Enzyme-induced biodegradation of polycarbonate polyurethanes10.1002/1097-4636(20010915)56:4<516::AID-JBM1123>3.0.CO;2-B ↗
12. Enzyme-induced biodegradation of polycarbonate-polyurethanes10.1002/1097-4636(20011215)57:4<597::AID-JBM1207>3.0.CO;2-T ↗
13. Enzyme induced biodegradation of polycarbonate-polyurethanes10.1016/S0142-9612(02)00563-X ↗
14. Changes in macrophage function and morphology due to biomedical polyurethane surfaces undergoing biodegradation10.1002/jcp.10412 ↗
15. The effect of phospholipids on the biodegradation of polyurethanes by lysosomal enzymes10.1163/156856297X00317 ↗
16. Neutrophil-mediated biodegradation of medical implant materials10.1002/1097-4652(200101)186:1<95::AID-JCP1008>3.0.CO;2-0 ↗
17. Biodegradation of polycarbonate-based polyurethanes by the human monocytes-derived macrophage and U937 cell systems10.1002/jbm.10286 ↗
18. Chemical modification of the histidine residue in phospholipase A2 (Naja naja naja). A case of half-site reactivity10.1016/S0021-9258(17)40568-0 ↗
19. Slow- and tight-binding inhibitors of the 85-kDa human phospholipase A210.1021/bi00074a003 ↗
20. Binding of quinacrine to acidic phospholipids and pancreatic phospholipase A2. Effects on the catalytic activity of the enzyme10.1021/bi980430q ↗
21. Inhibition of macrophage Ca2+-independent phospholipase A2 by bromoenol lactone and trifluoromethyl ketones10.1074/jbc.270.1.445 ↗
22. Effects of DMSO-induced differentiation on arachidonate mobilization in the human histiocytic lymphoma cell line U93710.1016/0167-4889(94)90229-1 ↗
23. Phospholipase A2 regulation of arachidonic acid mobilization10.1016/S0014-5793(02)03413-0 ↗
24. Cellular components that functionally interact with signaling phospholipase A2s10.1016/S1388-1981(00)00118-9 ↗
25. The functions of five distinct mammalian phospholipase A2s in regulating arachidonic acid release. Type IIa and type V secretory phospholipase A2s are functionally redundant and act in concert with cytosolic phospholipase A210.1074/jbc.273.23.14411 ↗
26. Modified low density lipoprotein enhances the secretion of bile salt-stimulated cholesterol esterase by human monocyte-macrophages. species-specific difference in macrophage cholesteryl ester hydrolase10.1074/jbc.272.45.28666 ↗
27. Biology of monocyte-specific esterase10.3109/10428190009065825 ↗
28. Structure and function of phospholipase A2 receptor10.1016/0163-7827(94)00009-B ↗
29. Clearance of group X secretory phospholipase A2 via mouse phospholipase A2 receptor10.1016/S0014-5793(01)03173-8 ↗
30. Phospholipase A2 receptor10.1016/S0090-6980(02)00022-9 ↗
31. Biological and pathological functions of phospholipase A(2) receptor10.1006/abbi.1999.1511 ↗
32. Toll-like receptors10.1186/gb-2002-3-8-reviews3011 ↗